Breaking News Instant updates and real-time market news.

2017-09-15 08:06:53

GLPG

Galapagos NV

$103.47

2 (1.97%)

08:06

09/15/17

09/15

08:06

09/15/17

08:06

Galapagos NV price target raised to $120 from $101 at Stifel

After hosting a call with two key opinion leaders on idiopathic pulmonary fibrosis, Stifel analyst Adam Walsh noted that the physicians expressed the view that the efficacy of GLPG1690 in the Phase 2 FLORA trial "was as good as one could have hoped for." As a result of the positive physician feedback, he increased his probability of success for '1690 to 15% from 10% and raised his price target on Galapagos to $120 from $101. Walsh keeps a Buy rating on Galapagos shares.

GLPGGalapagos NV

$103.47

2 (1.97%)

08/11/17

STFL

08/11/17UPGRADESTFLBuy

Galapagos NV upgraded to Buy from Hold at Stifel

08/11/17

STFL

08/11/17UPGRADETarget $101STFLBuy

Stifel upgrades Galapagos with $101 target on 'clearly positive' data

Stifel analyst Adam Walsh upgraded Galapagos NV to Buy from Hold and raised his price target for the shares to $101 from $83. The stock closed yesterday up 11%, or $7.89, to $81.06. The early Phase 2 results for wholly-owned GLPG1690 in idiopathic pulmonary fibrosis were "clearly positive," Walsh tells investors in a research note. The analyst included the drug in his model with a "very reasonable" 10% probability of success. Further, he sees "reduced downside risk" associated with Galapagos' cystic fibrosis triple combo.

08/14/17

JEFF

08/14/17NO CHANGEJEFFBuy

Expert IPF call positive for FibroGen, says Jefferies

Jefferies analyst Michael Yee says his call with two idiopathic pulmonary fibrosis experts was net positive for FibroGen (FGEN). Based on the available data, the experts estimated a 30%-40%-plus probability of success in Phase 3 for the company. The experts were "more conservative in the interpretation" of the data reported by Galapagos NV (GLPG), Yee tells investors in a research note. He reiterates a Buy rating on FibroGen given the "underappreciated value" for FG-3019 in IPF.

UP AFTER EARNINGS: Cintas (CTAS), up 2.9%... Micron (MU), up 2.8%. ALSO HIGHER: Editas Medicine (EDIT), up 3.1% after it received the EMA's orphan medicinal product designation for EDIT-101... Twitter (TWTR), up 1.8% after it said it will start testing longer, 280-character tweets with a small group. DOWN AFTER EARNINGS: Nike (NKE), down 3.2%. ALSO LOWER: Kornit Digital (KRNT), down 12.2% after it cut its third quarter revenue guidance... Westlake Chemical Partners (WLKP), down 8.3% after it filed to sell 4.5M units for limited partners... Intra-Cellular (ITCI), down 7.2% after it filed to sell $150M in common stock... Ascendis Pharma (ASND), down 4.3% after it announced an offering of $125M of ADSs.